Meeting
2014 Genitourinary Cancers Symposium
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
Authors
A. Ari Hakimi
Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
A. Ari Hakimi , Irina Ostrovnaya , Anders Jacobsen , Jonathan A. Coleman , Paul Russo , Roy Mano , Alexander Sankin , Robert John Motzer , Mark Purdue , Mark Pomerantz , Matthew L Freedman , Toni K. Choueiri , James Hsieh , Robert J. Klein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 395)
DOI
10.1200/jco.2014.32.4_suppl.395
Abstract #
395
Poster Bd #
C3
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Genomic predictors of recurrence (R) or progression (P) in high grade T1 (HGT1) non-muscle invasive (NMI) bladder cancer.
First Author: Joaquim Bellmunt
Poster
2023 ASCO Breakthrough
Genomic predictors for early recurrence of hepatocellular carcinoma (HCC) after curative resection.
First Author: Lisha Huang
Poster
2023 ASCO Annual Meeting
Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma.
First Author: Kelly N. Fitzgerald
Poster
2020 Genitourinary Cancers Symposium
Neutrophil-to-lymphocyte ratio as a predictor of oncologic outcomes in locally advanced non-metastatic clear cell renal carcinoma.
First Author: Gilberto Rodrigues